At the time of writing, Emergent Biosolutions Inc [EBS] stock is trading at $9.60, up 2.89%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The EBS shares have gain 9.71% over the last week, with a monthly amount glided 13.34%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Emergent Biosolutions Inc [NYSE: EBS] stock has seen the most recent analyst activity on August 22, 2024, when Rodman & Renshaw initiated its Buy rating and assigned the stock a price target of $16. Previously, The Benchmark Company upgraded its rating to Buy on March 07, 2024, and kept the price target unchanged to $5. The Benchmark Company downgraded its rating to a Hold. The Benchmark Company upgraded its rating to a Buy but $22 remained the price target by the analyst firm on April 10, 2023. JP Morgan downgraded its rating to Underweight for this stock on March 17, 2023, and downed its price target to $9. In a note dated November 10, 2022, The Benchmark Company downgraded an Hold rating on this stock.
For the past year, the stock price of Emergent Biosolutions Inc fluctuated between $1.42 and $15.10. Currently, Wall Street analysts expect the stock to reach $51.5 within the next 12 months. Emergent Biosolutions Inc [NYSE: EBS] shares were valued at $9.60 at the most recent close of the market. An investor can expect a potential return of 436.46% based on the average EBS price forecast.
Analyzing the EBS fundamentals
According to Emergent Biosolutions Inc [NYSE:EBS], the company’s sales were 1.10B for trailing twelve months, which represents an -24.62% plunge. Gross Profit Margin for this corporation currently stands at 0.23% with Operating Profit Margin at -0.37%, Pretax Profit Margin comes in at -0.52%, and Net Profit Margin reading is -0.53%. To continue investigating profitability, this company’s Return on Assets is posted at -0.39, Equity is -0.98 and Total Capital is -0.45. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 2.24.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.24 points at the first support level, and at 8.88 for the second support level. However, for the 1st resistance point, the stock is sitting at 9.93, and for the 2nd resistance point, it is at 10.25.
Ratios To Look Out For
It is important to note that Emergent Biosolutions Inc [NYSE:EBS] has a current ratio of 1.06. Further, the Quick Ratio stands at 0.54, while the Cash Ratio is 0.11. Considering the valuation of this stock, the price to sales ratio is 0.47, the price to book ratio is 1.31.
Transactions by insiders
Recent insider trading involved Zoon Kathryn C, Director, that happened on Jun 04 ’24 when 10000.0 shares were sold. Director, Zoon Kathryn C completed a deal on May 29 ’24 to sell 1830.0 shares. Meanwhile, Director Zoon Kathryn C sold 1089.0 shares on May 21 ’24.
